BioCentury
ARTICLE | Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

June 3, 2020 1:04 AM UTC

Allogene raises $550M follow-on
Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $550 million late Monday through the sale of 11.7 million shares at $47, a 2% discount to its Friday close of $48.16, before proposing the offering early Monday. The company’s Phase I data reported at the ASCO meeting last month provided the first evidence that allogeneic CAR T therapies could challenge marketed autologous therapies on safety and efficacy (see “Allogene’s Allogeneic CAR T Data”).
Adaptimmune raises $225.5M follow-on
Adaptimmune Therapeutics plc (NASDAQ:ADAP) raised $225.5 million late Monday through the sale of 20.5 million ADSs at $11. The price is in-line with its close of $11.07 on Monday; the T cell therapy proposed the offering early that day.

Big data investor DCVC aiming for $275M fund
DCVC Bio II is seeking to raise $275 million for its second bio-focused fund. The firm’s first such fund targeted $250 million...